– USA, FL – Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced the appointment of Dr. Dan Curran (MD) to its Board of Directors.
About Dr. Daniel Curran
Dr. Dan Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also serves as CEO of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases.
From 2008 to 2023, Dr. Dan Curran held roles of increasing responsibility at Takeda Pharmaceutical Company, serving as SVP and Head of the Rare Genetics and Hematology Therapeutic Area Unit from January 2019 through December 2023.
Before his tenure at Takeda, Dr. Dan Curran served as VP of Corporate Development at Millennium Pharmaceuticals, Inc., from 1999 to 2008. Earlier in his career, he held a business development role in the product planning and acquisition group at DuPont Merck Pharmaceuticals.
Dr. Dan Curran served on the board of directors of Tome Biosciences, a private biotechnology company, and currently serves on the Board of Directors of Xilio Therapeutics, Inc. (NASDAQ: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies to significantly improve outcomes for people living with cancer without the systemic side effects of current I-O treatments.
Dr. Dan Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.S. in chemistry from King’s College.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more: https://catalystpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.